EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations
The 2025 EULAR rheumatoid arthritis recommendations abandon prognostic-factor stratification after methotrexate failure and endorse less frequent laboratory monitoring after early tolerance, both directly relevant to ambulatory pharmacists managing DMARD regimens and adherence.
methotrexateglucocorticoidsbDMARDsJAK inhibitorstsDMARDscsDMARDsleflunomidesulfasalazinerheumatoid arthritisEULARtreat-to-targetbiosimilarsguideline updatedeprescribingmedication monitoringAmbulatory Care / MTM
Background Information
Enhance medication safety during care transitions with targeted interventions.
Care transitions are vulnerable points for medication errors, affecting patient safety and adherence. Multicomponent interventions for high-risk patients significantly reduce medication discrepancies and improve adherence. While effective, these interventions are resource-intensive and their implementation may be limited but offer cost-effective benefits in specific conditions. Multifaceted intervention during care transitions enhances medication safety and adherence.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Schnipper JL Medication Management During Care Transitions: Reducing Errors and Enhancing Adherence. The Medical clinics of North America. 2026;110(4):583-596. doi:10.1016/j.mcna.2025.11.017
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.